The FDA wants it off the market. European regulators are investigating data-integrity concerns. And now, a pharma company selling the drug in Japan is warning doctors against writing new prescriptions. Still, Amgen remains resolute in …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
